title: [Thromboprophylaxis in pregnant women should be individually tailored].
abstract: Roeters van Lennep et al. recently evaluated efficacy and safety of thromboprophylaxis with low dose low-molecular-weight heparin (LMWH) in women with intermediate and high risk of pregnancy-related venous thromboembolism (VTE). Lessons to be drawn from this study are that the risk of VTE should be estimated preconceptionally, that the current LMWH prophylaxis is sufficient during pregnancy and the post-partum period for women with an intermediate risk of VTE, that from a haemostatic point of view the post-partum period does not end at 6 weeks but at 3 months, and that the prophylactic LMWH dosage is insufficient in 1 out of 20 women with a high risk of VTE.
authors.affiliation: Maastricht Universitair Medisch Centrum, afd. Obstetrie en Gynaecologie, Maastricht, the Netherlands. marc.spaanderman@mumc.nl
authors.forename: Marc A C
authors.initials: MA
authors.lastname: Spaanderman
mesh_terms: D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control*; D018570:Risk Assessment; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000517:prevention & control*
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight